Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05675930 · ClinicalTrials.gov registry record · Phase 2

A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant

A Phase 2 study of Graft-Versus-Host Disease and GvHD, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
44
Enrollment target
9
Study locations

NCT05675930 is a Phase 2 study of Graft-Versus-Host Disease and GvHD that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 44 participants, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (46% lower). The trial reports 9 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05675930, a Phase 2 study of Graft-Versus-Host Disease and GvHD, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
44 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.

Conditions Studied

Graft-Versus-Host Disease GvHD Undefined

Interventions

  • DEVICE Photobiomodulation Therapy
  • OTHER Placebo sham device

Study Locations (9)

New York

  • Memorial Sloan Kettering Cancer Center @ Commack (Consent only) - Commack
  • Memorial Sloan Kettering Westchester (Consent only) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Cancer Center @ Nassau (Consent only) - Uniondale

New Jersey

  • Memorial Sloan Kettering at Basking Ridge (Consent only) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Consent only) - Middletown
  • Memorial Sloan Kettering Cancer Center @ Bergen (Consent only) - Montvale

Maryland

  • National Institute of Health (Data Collection AND Specimen Analysis) - Bethesda

Pennsylvania

  • University of Pittsburgh Medical Center (Data Collection Only) - Pittsburgh

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2022-12-22
Est. Completion 2026-12-22
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05675930

The ClinicalTrials.gov registry entry for NCT05675930 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (46% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 2 interventions - of which Photobiomodulation Therapy is the first listed.

NCT05675930 reports 9 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, Maryland.

Frequently Asked Questions

What is clinical trial NCT05675930 about?

NCT05675930 is a clinical study titled "A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant". The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.

What is the current status of trial NCT05675930?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2022-12-22. Estimated completion is 2026-12-22.

What conditions does trial NCT05675930 study?

This clinical trial studies the following conditions: Graft-Versus-Host Disease, GvHD, Undefined.

What interventions are being tested in trial NCT05675930?

The interventions under investigation include: Photobiomodulation Therapy (DEVICE), Placebo sham device (OTHER).

Who is sponsoring clinical trial NCT05675930?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05675930 being conducted?

This trial has 9 study locations across Maryland, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Graft-Versus-Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Graft-Versus-Host Disease

All registered trials for this condition

GvHD

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.